Daewon Pharmaceutical teams with E-Land’s Kim’s Club to launch 14 health supplements
Daewon Health said Feb. 23 it will launch 14 premium health functional foods in collaboration with Kim’s Club, a supermarket brand operated by E-Land Retail.
The lineup includes a multivitamin, milk thistle, lutein, calcium and coenzyme Q10. The products are designed by age, gender and health goal, and the packaging includes suggested uses tied to common health concerns to help shoppers choose.
Daewon Health said all products are formulated to meet at least 100% of Korean nutrient intake standards. It said it combined key ingredients with complementary ingredients to improve nutritional balance and priced the products at 5,000 won or less for a one-month supply to reduce the burden on consumers.
Yuhan launches ‘Becompl’ daily vitamin shots in three versions
Yuhan said Feb. 23 it launched three products under its premium daily care brand Becompl, designed to help manage daily condition by time of day. The company said the products use a dual format that combines a tablet and liquid in one bottle, allowing consumers to take them without water and improving portability and convenience.
Becompl Morning Shot is aimed at liver health. Yuhan said the 30 mL portable product contains milk thistle and Rhodiola rosea extract for easy use on the way to work.
Becompl All Day Shot is a premium multivitamin that includes 20 functional ingredients in one bottle. Centered on high-dose B vitamins needed for energy metabolism, it also combines vitamins C and E with minerals and may help with antioxidant support, the company said.
Becompl Good Night is designed to improve sleep quality and is intended for nighttime use. Yuhan said it contains lime peel extract, a citrus-derived ingredient that may help support sleep health.
Kolon Life Science to broaden indications for next-generation gene therapy candidates
Kolon Life Science said Feb. 23 it plans to add new indications for drug candidates KLS-3021 and KLS-2031 and strengthen the foundation for global commercialization.
KLS-3021 is a next-generation anticancer gene therapy candidate that loads therapeutic genes (PH-20, IL-12 and sPD1-Fc) onto a recombinant vaccinia virus engineered for greater selectivity toward cancer cells. The company said it is designed to combine the virus’ direct tumor-killing mechanism with breakdown of tumor stroma to help immune cells penetrate cancer tissue, while also inducing an anticancer immune response.
To diversify indications for KLS-3021, Kolon Life Science said it is expanding research to include head and neck squamous cell carcinoma and triple-negative breast cancer. Another pipeline candidate, KLS-2031, is a recombinant adeno-associated virus (rAAV)-based gene therapy designed to express the genes GAD65, GDNF and IL-10, which are involved in suppressing neuroinflammation and regulating overexcited pain signaling pathways.
The company said it is continuing to submit papers on preclinical results related to diabetic peripheral neuropathy and is also pursuing additional indications.
AI may enable earlier detection of Parkinson’s disease, Samsung Medical Center says
Samsung Medical Center’s AI Research Center said Feb. 23 it has confirmed the potential for earlier diagnosis of neurodegenerative diseases, including Parkinson’s disease and Parkinson-plus syndromes, using multimodal AI that analyzes clinical data such as gait, voice and brain imaging together.
Parkinson’s disease is often diagnosed late because early symptoms are not clear. By the time tremors or gait problems appear, the disease may already be significantly advanced.
A research team led by neurologist Cho Jin-hwan and radiologist Jeong Myeong-jin collected and standardized clinical information — including gait, voice and brain imaging — from about 500 patients over four years: 363 with Parkinson’s disease, 67 with progressive supranuclear palsy and 61 with multiple system atrophy. The team built an integrated database and developed a gait-based fall-risk prediction model, a voice-test-based Parkinson’s classification system, and an MRI-based automated brain-structure analysis model.
In clinical evaluations, the hospital said the voice-based severity classification model, the MRI-based disease differentiation model, and a fall prediction model that analyzes gait and brain imaging together all showed high accuracy. Samsung Medical Center added that the models can also present the basis for their decisions.
Cho said, “The earlier Parkinson’s disease is detected, the better the effect of drug treatment, and rehabilitation can slow progression,” adding that AI will help early diagnosis by quickly integrating results from multiple tests.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.